Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ: NAMS )

25.95 +0.32 (+1.25%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 170,031
Open 25.61
Bid (Size) 24.89 (1)
Ask (Size) 27.50 (50)
Prev. Close 25.63
Today's Range 25.23 - 26.00
52wk Range 10.50 - 27.29
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?
These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN. 
Via Benzinga
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From NewAmsterdam Pharma N.V.
Via GlobeNewswire

Performance

YTD
+117.15%
+117.15%
1 Month
+23.28%
+23.28%
3 Month
+66.88%
+66.88%
6 Month
+31.93%
+31.93%
1 Year
+127.83%
+127.83%

More News

Read More
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
Via Investor's Business Daily
Top 3 Health Care Stocks That May Collapse This Quarter
Via Benzinga
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Forecasting The Future: 5 Analyst Projections For NewAmsterdam Pharma
Via Benzinga
NewAmsterdam Pharma Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
What 4 Analyst Ratings Have To Say About NewAmsterdam Pharma
Via Benzinga
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?
Via Benzinga
United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
NewAmsterdam Pharma Soars 41% On An Surprise Benefit From Cholesterol Drug
Via Investor's Business Daily
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Expert Ratings For NewAmsterdam Pharma
Via Benzinga
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study
Via Investor's Business Daily
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.